Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
Androgen receptor (AR) splice variants (AR-Vs) have been discussed as a biomarker in prostate cancer (PC). However, some reports question the predictive property of AR-Vs. From a mechanistic perspective, the connection between AR full length (AR-FL) and AR-Vs is not fully understood. Here, we aimed...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
05 April 2023
|
| In: |
Biomarker Research
Year: 2023, Volume: 11, Pages: 1-14 |
| ISSN: | 2050-7771 |
| DOI: | 10.1186/s40364-023-00481-w |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s40364-023-00481-w |
| Author Notes: | Neele Wüstmann, Konstantin Seitzer, Verena Humberg, Julia Vieler, Norbert Grundmann, Julie Steinestel, Dorothee Tiedje, Stefan Duensing, Laura-Maria Krabbe, Martin Bögemann, Andres Jan Schrader, Christof Bernemann and Katrin Schlack |
| Summary: | Androgen receptor (AR) splice variants (AR-Vs) have been discussed as a biomarker in prostate cancer (PC). However, some reports question the predictive property of AR-Vs. From a mechanistic perspective, the connection between AR full length (AR-FL) and AR-Vs is not fully understood. Here, we aimed to investigate the dependence of AR-FL and AR-V expression levels on AR gene activity. Additionally, we intended to comprehensively analyze presence of AR-FL and three clinically relevant AR-Vs (AR-V3, AR-V7 and AR-V9) in different stages of disease, especially with respect to clinical utility in PC patients undergoing AR targeted agent (ARTA) treatment. |
|---|---|
| Item Description: | Gesehen am 17.05.2023 |
| Physical Description: | Online Resource |
| ISSN: | 2050-7771 |
| DOI: | 10.1186/s40364-023-00481-w |